Table 1 Baseline characteristics of the 1,936 cardiac surgery patients included in the study
| Â | Â | Statin Treatment | Â | |
|---|---|---|---|---|
| Â | All patients n = 1936 | Yes n = 1322 | No n = 614 | p value |
Clinical data | Â | Â | Â | Â |
   Age [years] | 66+10 | 65+10 | 67+10 | 0.01 |
   Male, % | 99% | 99% | 99% | 0.46 |
   BMI [kg/m2] | 29.4+5.4 | 30+5.4 | 29+5.3 | 0.03 |
   Diabetes mellitus, % | 34% | 35% | 30% | 0.03 |
   Hypertension, % | 60% | 81% | 73% | 0.001 |
   Chronic lung disease, % | 23% | 22% | 26% | 0.06 |
   Peripheral vascular disease, % | 30% | 30% | 30% | 0.90 |
   Cerebrovascular disease, % | 22% | 22% | 21% | 0.49 |
   Current Smoking, % | 68% | 21% | 17% | 0.03 |
   History of myocardial infarction, % | 42% | 46% | 33% | <0.0001 |
   History of heart surgery, % | 9% | 9% | 9% | 0.82 |
   LV ejection fraction <50%, % | 41% | 42% | 47% | 0.05 |
   NYHA heart failure class III/IV, % | 35% | 33% | 39% | 0.01 |
   History of atrial fibrillation, % | 5.7% | 6.3% | 4.6% | 0.13 |
   Chronic kidney disease, % | 3.7% | 11% | 13% | 0.53 |
   Cardiomegaly, % | 27% | 25% | 31% | 0.01 |
Preoperative medications | Â | Â | Â | Â |
   BetaBlockers, % | 53% | 57% | 46% | <0.0001 |
   ACE-I or ARB, % | 72% | 73% | 69% | 0.59 |
   Gemfibrozil, % | 8% | 8% | 7% | 0.59 |
   Calcium Chanel blocker, % | 21% | 23% | 17% | 0.01 |
   Amiodarone, % | 16% | 16% | 17% | 0.31 |
   Diuretics, % | 41% | 40% | 43% | 0.13 |
   Digoxin, % | 8% | 7% | 12% | <0.0001 |